Quinolone antibiotics
TDM Pham, ZM Ziora, MAT Blaskovich - Medchemcomm, 2019 - pubs.rsc.org
The quinolone antibiotics arose in the early 1960s, with the first examples possessing a
narrow-spectrum of activity with unfavorable pharmacokinetic properties. Over time, the …
narrow-spectrum of activity with unfavorable pharmacokinetic properties. Over time, the …
Pathophysiology and management of pulmonary infections in cystic fibrosis
RL Gibson, JL Burns, BW Ramsey - American journal of respiratory …, 2003 - atsjournals.org
This comprehensive State of the Art review summarizes the current published knowledge
base regarding the pathophysiology and microbiology of pulmonary disease in cystic …
base regarding the pathophysiology and microbiology of pulmonary disease in cystic …
Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria
LJV Piddock - Clinical microbiology reviews, 2006 - Am Soc Microbiol
Efflux pump genes and proteins are present in both antibiotic-susceptible and antibiotic-
resistant bacteria. Pumps may be specific for one substrate or may transport a range of …
resistant bacteria. Pumps may be specific for one substrate or may transport a range of …
The fluoroquinolone antibacterials: past, present and future perspectives
PC Appelbaum, PA Hunter - International journal of antimicrobial agents, 2000 - Elsevier
The history of the development of the quinolones is described from the first quinolone,
nalidixic acid, via the first 6-fluorinated quinolone norfloxacin, to the latest extended …
nalidixic acid, via the first 6-fluorinated quinolone norfloxacin, to the latest extended …
The quinolones: past, present, and future
VT Andriole - Clinical infectious diseases, 2005 - academic.oup.com
The quinolone class of antimicrobial agents has generated considerable interest since its
discovery> 40 years ago. Substantial progress has been made in our understanding of the …
discovery> 40 years ago. Substantial progress has been made in our understanding of the …
Mechanisms of action and resistance of older and newer fluoroquinolones
DC Hooper - Clinical infectious diseases, 2000 - academic.oup.com
The fluoroquinolones interact with 2 bacterial targets, the related enzymes DNA gyrase and
topoisomerase IV, both of which are involved in DNA replication. Quinolones form …
topoisomerase IV, both of which are involved in DNA replication. Quinolones form …
Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa
GM Rossolini, E Mantengoli - Clinical Microbiology and …, 2005 - Wiley Online Library
Pseudomonas aeruginosa is one of the leading causes of nosocomial infections. Severe
infections, such as pneumonia or bacteraemia, are associated with high mortality rates and …
infections, such as pneumonia or bacteraemia, are associated with high mortality rates and …
Fluoroquinolones, tuberculosis, and resistance
AS Ginsburg, JH Grosset, WR Bishai - The Lancet infectious …, 2003 - thelancet.com
Although the fluoroquinolones are presently used to treat tuberculosis primarily in cases
involving resistance or intolerance to first-line antituberculosis therapy, these drugs are …
involving resistance or intolerance to first-line antituberculosis therapy, these drugs are …
Hospital-acquired pneumonia: risk factors, microbiology, and treatment
JP Lynch III - Chest, 2001 - Elsevier
Pneumonia complicates hospitalization in 0.5 to 2.0% of patients and is associated with
considerable morbidity and mortality. Risk factors for hospital-acquired pneumonia (HAP) …
considerable morbidity and mortality. Risk factors for hospital-acquired pneumonia (HAP) …
Application of fluoroquinolone pharmacodynamics
DH Wright, GH Brown, ML Peterson… - Journal of …, 2000 - academic.oup.com
Pharmacodynamics provides a rational basis for optimizing dosing regimens by describing
the relationship between drug, host and antimicrobial effect. The successful identification of …
the relationship between drug, host and antimicrobial effect. The successful identification of …